ESR1 and breast carcinoma: While ER signaling remains central to endocrine therapy in ER-α-positive breast cancer, integrin αvβ3-mediated non-genomic estrogen signaling—particularly via GPER—contributes to tumor survival and chemoresistance in ER-α-negative and TNBC subtypes.